CHAPTER 93 Radiofrequency Denervation
INTRODUCTION
Low back pain is ubiquitous to mankind by virtue of our upright posture. Traditionally, it has been believed that most episodes of spinal pain are short lived and that at least 90% of patients with low back pain recover in about 6 weeks with or without treatment.1–3
Contrary to this prior assumption of only 10–20% patients experiencing recurrent or chronic symptoms after an initial episode of low back pain, recent literature puts that number as high as 35–79%.4–7
The challenge lies, in this subgroup of subjects, to identify the specific pain generator so that appropriate interventional therapy may be initiated as and when indicated. The study by Kuslich et al.8 identified along with intervertebral disc, dura, ligaments, fascia, and muscles, zygapophyseal or facet joints as capable of transmitting pain in the low back region. Even prior to this anatomical study, Goldthwait9 in 1911 first recognized lumbar zygapophyseal joints as potential source of low back pain. He believed that joint asymmetry could result in pain secondary from nerve root pressure. Subsequently, in 1933, Ghormley10 first coined the term ‘facet syndrome’ as lumbosacral pain with or without sciatic pain, occurring after a twisting or rotary strain of the lumbosacral region. Badgley11 in 1941 suggested that facet joints by themselves could be a primary source of low back pain separate from the nerve compression component. However, it was not until 1963 when Hirsch et al.12 demonstrated that the low back pain distributed along the sacroiliac and gluteal areas with referral to the greater trochanter could be induced by injecting hypertonic saline in the region of the lumbar facet joints. In 1976, Mooney and Robertson,13 and three years later McCall et al.14 used fluoroscopy to confirm the location of intra-articular lumbar facet joint injections in asymptomatic individuals, demonstrating reproduction of back and leg pain after injection of hypertonic saline. Eventually, Marks15 in 1989, followed by Fukui et al.16 in 1997, described the distribution of pain patterns after stimulating the lumbar facet joints.
Recent literature17 indicates that the prevalence of chronic lumbar zygapophyseal joint-mediated pain has a wide range that varies from 15% in the relatively younger patients, with confidence limits of 10–20%. This prevalence can be as high as 40% among the elderly population with confidence limits of 27–53%.18
ANATOMY
The lumbar facet or zygapophyseal joints are paired, true synovial, diarthrodial joints that form the posterior aspect of the respective intervertebral foramina. The joint consists of hyaline cartilage, a synovial membrane, a fibrous capsule, and nociceptive fibers transmitted via the medial branches of the dorsal rami.19,20 These facet joints are innervated by the medial branches of the dorsal rami (posterior primary rami) that exit the intervertebral foramina. The posterior primary rami travel posteriorly over the base of the transverse process. The dorsal ramus divides into a medial, an intermediate, and a lateral branch. The lateral branch ascends from the dorsal ramus just before it reaches the transverse process. The medial branch passes under the mammilloaccessory ligament and sends branches to the adjacent facet joint, the facet joint below, and the more medial erector spinae muscles. Thus, the joint is typically innervated from a branch at the same level and a branch originating from the foramen above. In contrast, the dorsal ramus at the fifth lumbar vertebral level (L5) travels between the ala of the sacrum and its superior articular process, which divides into the medial and lateral branches at the caudal edge of the process, the medial branch continuing medially, where it innervates the lumbosacral joint.21–23
Neuroanatomical studies12,24–26 indicate that the facet joint capsule is richly innervated, containing both free and encapsulated endings, and can undergo extensive stretch under physiological loading.27 It has been reported that protein gene product (PGP) 9.5, substance P (SP), calcitonin gene-related peptide (CGRP), dopamine β-hydroxylase (DBH), vasoactive intestinal polypeptide (VIP), neural peptide Y (NPY), and choline acetyl transferase (chAT) immunoreactive (IR) fibers are present within the human facet joint capsule.21,26,28–30 Ashton et al.31 confirmed immunoreactivity for SP, CGRP, and VIP in surgically removed human facet joint capsule. A subsequent anatomical study confirmed higher concentration of inflammatory cytokines in facet joint tissue from patients with lumbar spinal stenosis than in lumbar disc herniations, suggesting that these cytokines may have some contribution to the etiology of symptoms in degenerative spinal stenosis.32
PATHOPHYSIOLOGY
With aging, the changes that occur in the zygapophyseal joints are the same as those seen in any diarthrodial joint. The earliest change is synovitis, which may persist with the formation of a synovial fold which projects into the joint space itself. Later, degenerative changes set in gradually, and eventually become more marked. Eventually, the capsular laxity allows for subluxation of the joint surfaces. Continued degeneration mainly due to repeated torsional strains results in the formation of subperiosteal osteophytes, and possibly subchondral synovial cysts. The end result is that of gross articular degeneration, with almost complete loss of articular cartilage, and formation of bulbous zygapophyseal joints and marked periarticular fibrosis. The pathogenesis of a degenerative cascade in the context of a three-joint complex involving the intervertebral disc and the adjacent zygapophyseal joint also leads to the assumption that the degenerative changes within the disc are also believed to lead to associated facet degeneration.33–35
PAIN PATTERNS
The clinical presentation of lumbar zygapophyseal joint-mediated low back pain appears to overlap considerably with the presentation of low back pain due to various other etiologies. Lumbar facet joints have been shown to be capable of producing pain in the low back and referred pain in the lower extremity in normal volunteers.13–16 McCall et al.14 concluded that pain referral patterns overlap between the upper and lower lumbar spine. Marks15 also studied patterns of pain induced from lumbar facet joints, from the posterior primary rami of L5, and from the medial articular branches of the posterior primary rami from T11 to L4. He observed no consistent segmental or somatic referral pattern. Marks also concluded that pain referred to the buttocks or trochanteric region occurred mostly from the L4 and L5 levels, while inguinal or groin pain was produced from L2 to L5. This latter finding led to the conclusion that the nerves innervating the joints gave rise to distal referral of pain more commonly than the facet joint itself. Fukui et al.16 concluded that the major site of referral pain from the L1–2 to L4–5 joints was the lumbar region itself. However, stimulation of the L5–S1 joint caused referred spinal pain as well as gluteal pain. Referred pain into the lower extremities was not observed by Fukui et al.16 as was reported by Mooney and Robertson.13 However, it must not be overlooked that in the study by Mooney and Robertson, the relatively large volume of the injectate (3 cc) used may very well have inadvertently anesthetized structures other than the facet joint intended. In essence, these studies indicate that there is no clear dermatomal or somatic pattern that is diagnostic of lumbar facet joint-mediated pain and an overlap with a varied pattern is the norm.
DIAGNOSIS
All this being said, there is no identified correlation between a clinical picture or any imaging study used, such as the magnetic resonance imaging (MRI), computed tomography (CT) scan, single photon emission computed tomography (SPECT), or radionuclide bone scan in diagnosing pain mediated via the lumbar zygapophyseal joint.36–40 Simple static radiographs of the lumbar spine, and also dynamic images including standing flexion–extension films, may reveal evidence of arthritis involving the lumbar zygapophyseal joint as commonly in asymptomatic individuals as in patients with axial low back pain. What remains contentious is how lumbar zygapophyseal joint-mediated pain should be diagnosed.
Diagnostic injections
The only available means of establishing a diagnosis of lumbosacral zygapophyseal joint-mediated pain is to utilize diagnostic injections. Diagnostic blockade of a structure with a nerve supply with ability to generate pain can be performed to test the hypothesis that the target structure is the source of symptoms. If pain is relieved by blocking the medial branch or the zygapophyseal joint itself, the joint may be considered prima facie to be the source of pain.41 Pain relief is considered as the essential criterion, rather than provocation of pain from stimulating the target area.
The choice lies with the spine interventionist whether to pursue an intra-articular zygapophyseal joint injection or anesthetize the medial branches of the dorsal rami that innervate the target joint. Debate continues regarding the appropriateness of intra-articular injections or medial branch blocks. For diagnostic intra-articular injection only a small volume (0.5–0.8 cc) of the local anesthetic agent is to be injected. Using small aliquots of local anesthetic will minimize extravasation of the anesthetic agent and necessarily diminish the frequency of a false-positive response. In essence the specificity of the diagnostic injection is enhanced. A small amount (0.2 cc) of contrast medium should be instilled to ensure an intra-articular spread. A partial arthrogram ensures appropriate needle placement and protects against false appreciation of joint entry and venous infiltration.42 Similarly, when a medial branch block is performed, contrast should be instilled prior to the actual injection of the anesthetic agent to ensure against venous uptake. Theoretically, medial branch injections may be more specific because there is a less likelihood of anesthetizing the epidural space or the neural foramina as long as the anesthetic volume is limited to 0.5 cc. The author prefers to peruse an intra-articular injection in the younger patient population where the joint is not affected by significant arthritis. A medial branch block is preferred in the elderly where it may be technically difficult to access the severely arthritic zygapophyseal joint or when lack of adequate joint space is suspected. Kaplan et al.43 did find that medial branch blocks can fail to anesthetize the target joint in a minority of cases, ostensibly in 11% but possibly in as many as 31%, based on 95% confidence interval intervals. These authors have postulated that an aberrant or additional innervation of the targeted joint may provide for a pathway for persistent nociception. While not refuting the ability of the medial branch blocks to positively diagnose zygapophyseal joint pain, they warn that facet joint pain may be underdiagnosed by such diagnostic blocks.
Based on the response to a single diagnostic injection, the prevalence of the lumbar zygapophyseal joint pain in patients with chronic low back pain demonstrates a wide range of 7.7–75%.42,44–50 This wide range in numbers may represent a selection bias, variable population subsets, or even placebo responders. Similarly, a diagnosis cannot be made reliably on the basis of a single diagnostic injection, and false-positive rates as high as 38% have been demonstrated.51 To increase the sensitivity of these diagnostic injections it has been suggested that controlled diagnostic injection should include placebo injections utilizing normal saline.41 This may be accurate theoretically but is not practically viable, logistical, or ethical to use placebo injections in all patients presenting with low back pain presumably of lumbar facet origin. An attractive, reasonable alternative is the use of comparative local anesthetic blocks using two local agents with different duration of actions on two separate occasions.52–